UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

 Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934

 

For the Month of September 2013

 

000-55041
(Commission File Number)

  

CAN-FITE BIOPHARMA LTD.

(Exact name of Registrant as specified in its charter)

 

10 Bareket Street
Kiryat Matalon, P.O. Box 7537
Petach-Tikva 4951778, Israel
(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover
Form 20-F or Form 40-F.

 

Form 20-F þ Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1): ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7): ¨

 

 
 

 

On August 29, 2013, Can-Fite BioPharma Ltd. filed in Israel its unaudited interim consolidated financial statements as of June 30, 2013, a translation of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

2
 

 

Exhibit Index

  

Exhibit No.

Description

     
99.1   Can-Fite BioPharma Ltd.’s Unaudited Interim Consolidated Financial Statements as of June 30, 2013

 

3
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Can-Fite BioPharma Ltd.
   
Date:  September 16, 2013 By:  /s/ Motti Farbstein
  Motti Farbstein
  Chief Operating and Financial Officer

 

4